1. Scottish Renal Cancer Forum National Meeting 31st March 2016 Renal cancer survival Period of diagnosis: 2010-2012 Roger Black

2. Outline Data sources Inclusion/exclusion criteria Characteristics of the study population Statistical methods Results - National survival figures - Survival by selected characteristics/factors - International (European) comparisons Summary

3. Data sources Study population from Scottish Cancer Registry Socio-economic position based on Scottish Index of Multiple Deprivation (SIMD 2009) Co-morbidity indicators based on linked hospital inpatient/day case (SMR01) records - Charlson score (5-year look-back) Mortality records from National Records Scotland

4. Inclusion/Exclusion Criteria Including patients: Registered in the Scottish Cancer Registry Resident in Scotland at the time of diagnosis Incidence date in period 2010-2012 Renal cancer ICD10-C64 and ICDO(3):(83103; 82603; 83123; 83163; 83173; 83183;83193) Age 15-99 years at diagnosis Excluding: Death Certificate Only (DCO) registrations Incidental diagnosis at autopsy Age <15 or ≥100 years Emigrants Without a known NHS Board of residence in Scotland at the time of diagnosis Final cohort: 1,949 patients

5. How does survival compare with other cancers?

7. Characteristics of the cohort (1)

8. Characteristics of the cohort (2)

9. Survival by gender

10. Age specific and age standardised Survival

11. Survival by deprivation h

12. Survival by First Treatment

13. Survival by Charlson co-morbidity

14. Survival by Fuhrman Grade

15. Survival by Regional Cancer Network of diagnosis

16. Survival by NHS Board of diagnosis

17. Cross-tabs by Network of Diagnosis

18. European comparisons of survival Source: the EUROCARE-5 Study Period of diagnosis: 2000-2007 Outcome: 5-year age-standardized relative survival

19. Kidney Cancer, Europe, adults diagnosed 2000-2007. Age-standardized five-year relative survival (%)

20. Summary Survival from Renal Cancer is lower in: - Males vs females - Old vs young - Most deprived vs least deprived - Patients with co-morbidity (Charlson morbidity Index) - Fuhrman grade Survival by First treatment type is variable Significant differences by area of Diagnosis (regional network and NHS Board) Survival from Kidney Cancer in Scotland appears to be lower than in many other European countries